Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan 1;8(1):328-36.
eCollection 2015.

Decreased expression of TFPI-2 correlated with increased expression of CD133 in cholangiocarcinoma

Xia Chu  1 , Po Zhao  2 , Yali Lv  2 , Lin Liu  2
Affiliations

Decreased expression of TFPI-2 correlated with increased expression of CD133 in cholangiocarcinoma

Xia Chu et al. Int J Clin Exp Pathol. .

Abstract

Background: Recent findings suggest decreasing TFPI-2 expression plays a significant role in inhibiting cell migration and tumor invasion. The clinicopathological significance of the expression of TFPI-2 and its possible correlation with the expression of CD133 in cholangiocarcinoma remains to be solved.

Methods: We investigated if TFPI-2 was involved in the clinicopathological significance of cholangiocarcinoma. An immunohistochemical method was used to detect 218 cases of cholangiocarcinoma, 30 para-neoplastic and 20 normal bile ducts for their expression status of TFPI-2 and CD133, and then the results were analyzed with the patient's age, sex, tumor site and the histological grade, clinical stage as well as overall mean survival time.

Results: Compared with the para-neoplastic and normal cholangiocytes, the expression of TFPI-2 was obviously decreased while the expression of CD133 in carcinoma cells was increased. Carcinomas with low expression of TFPI-2 were significantly corresponding to the tumor site (P = 0.006), size (P = 0.005), histological grade (P = 0.0001) and clinical stage (P = 0.0001), but not to the age (P = 0.066) and sex (P = 0.411), respectively. By Kaplan-Meier survival analysis, the low expression of TFPI-2 was significantly correlative with the overall survival time (P = 0.0001). Further, the expression of TFPI-2 was found inversely correlative with the expression of CD133 (g = -0.3876, P < 0.0001).

Conclusions: Our finding suggests that the decreased expression of TFPI-2 may play an important role in the carcinogenesis and progression, and may become a new adjunct marker in the diagnosis and prognosis in cholangiocarcinoma. The expression of TFPI-2 may be inversely correlative with the expression of CD133.

Keywords: CD133; Cholangiocarcinoma; TFPI-2; immunohistochemistry; prognosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Expression of TFPI-2 in cholangiocarcinoma. TFPI-2 was lowly expressed positive in the membrane and cytoplasm of cancer cells in cholangiocarcinoma. (TFPI-2 ×400).
Figure 2
Figure 2
Kaplan-Meier survival analysis by TFPI-2 status (n = 218). The y-axis represents the percentage of patients; the x-axis, their survival in months. The green line represents TFPI-2- high expressive patients with a trend of better survival than the blue line representing TFPI-2- low expressive patients (Log rank = 45.149; P = 0.0001). Mean overall survival (OS) time was 31.1 months for the TFPI-2-high expressive group and 16.8 months for the TFPI-2- low expressive group.
Figure 3
Figure 3
Expression of CD133 and TFPI-2 protein in cholangiocarcinoma. CD133 was highly expressed (A) but TFPI-2 was negatively expressed (B) in the same cancerous glands in moderately differentiated cholangiocarcinoma. (CD133, TFPI-2 ×400).
Figure 4
Figure 4
Kaplan-Meier survival analysis by CD133 status (n = 218). The y-axis represents the percentage of patients; the x-axis, their survival in months. The green line represents CD133-high expressive patients with a trend of worse survival than the blue line representing CD133- low expressive patients. Mean survival (OS) time was 16.9 months for the CD133- high expressive group and 31.2 months for the CD133- low expressive group (Log rank = 41.642; P = 0.0001).
Figure 5
Figure 5
The inverse correlation between TFPI-2 and CD133. From left to right, expression of TFPI-2 compared with that of CD133 (n = 218) as low to low (1, n = 40), low to high (2, n = 74), high to low (3, n = 63) and high to high (4, n = 41) (r = -0.3876, P = 0.0001).
See this image and copyright information in PMC

References

    1. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thursz MR, Wasan H. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002;51(Suppl 6):VI1–VI9. - PMC - PubMed
    1. Gores GJ. A spotlight on cholangiocarcinoma. Gastroenterology. 2003;125:1536–1538. - PubMed
    1. Heron DE, Stein DE, Eschelman DJ, Topham AK, Waterman FM, Rosato EL, Alden M, Anne PR. Cholangiocarcinoma: the impact of tumor location and treatment strategy on outcome. Am J Clin Oncol. 2003;26:422–428. - PubMed
    1. Berman DM, Karhadkar SS, Maitra A, Montes-De-Oca R, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman JR, Watkins DN, Beachy PA. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumors. Nature. 2003;425:846–851. - PubMed
    1. Udagawa K, Yasumitsu H, Esaki M, Sawada H, Nagashima Y, Aoki I, Jin M, Miyagi E, Nakazawa T, Hirahara F, Miyazaki K, Miyagi Y. Subcellular localization of PP5/TFPI-2 in human placenta: a possible role of PP5/TFPI-2 as an anti-coagulant on the surface of syncytiotrophoblasts. Placenta. 2002;23:145–153. - PubMed

MeSH terms